Dark | Light
# NovoCure Limited Ordinary Shares (NVCR)

NovoCure's Optune Pax receives FDA approval for pancreatic cancer, but the stock faces downward pressure due to broader market trends.

### About NovoCure Limited Ordinary Shares
NovoCure Limited Ordinary Shares (NVCR) is a healthcare company focused on TTFields therapy for cancer treatment.  
NovoCure Limited Ordinary Shares uses the ticker $NVCR for trading. Listed in the [Stocks](/list/stocks) category within the [Healthcare](/list/stocks/healthcare) sectors.

### Insights
- NovoCure Limited Ordinary Shares (NVCR) social dominance hit [------] which is 823% higher than it's daily average.
- NovoCure Limited Ordinary Shares (NVCR) trading volume is up 182.93% from the previous week.
- NovoCure Limited Ordinary Shares (NVCR) social dominance is up 6433.33% from the previous [--] months.
- NovoCure Limited Ordinary Shares (NVCR) creators is up 1325.81% from the previous week.
- NovoCure Limited Ordinary Shares (NVCR) engagements is up 976.86% from the previous week.
- NovoCure Limited Ordinary Shares (NVCR) mentions is up 1142% from the previous week.
- NovoCure Limited Ordinary Shares (NVCR) posts created is up 6816.67% from the previous week.
- NovoCure Limited Ordinary Shares Creators hit a 52-Week high of [---] for the day
- NovoCure Limited Ordinary Shares Creators hit an all time of [---] for the day
- NovoCure Limited Ordinary Shares Mentions hit a 52-Week high of [---] for the day
- NovoCure Limited Ordinary Shares Mentions hit an all time of [---] for the day
- NovoCure Limited Ordinary Shares Engagements hit a 52-Week high of [-------] for the day

### Price: $11
![Price Line Chart](https://lunarcrush.com/gi/w:600/t:$nvcr/c:line/m:close/iv:1d.svg)  
[Price 24-Hour Time-Series Raw Data](/topic/$nvcr/time-series/close.tsv)  
Despite positive news like FDA approval for pancreatic cancer treatment, NVCR's price is experiencing downward pressure, likely due to broader market trends that are currently outweighing the positive social and corporate developments.  

24-Hour: -12.11%
7-Day: 8.38%
30-Day: -19.43%

1-Year High: $22.50 on 2025-02-15  
1-Year Low: $10 on 2026-02-09  
  
  
### AltRank: [---]
![AltRank Line Chart](https://lunarcrush.com/gi/w:600/t:$nvcr/c:line/m:alt_rank/iv:1d.svg)  
[AltRank 24-Hour Time-Series Raw Data](/topic/$nvcr/time-series/alt_rank.tsv)  
NovoCure Limited Ordinary Shares (NVCR) is currently AltRank #861 based on combined combined social and market metrics
Daily Average: [-----]  
[--] Week: [---] [----]  
[--] Month: [---] [------]  
[--] Months: [---] [------]  
[--] Year: [---] [----]  
1-Year High: [-----] on 2026-01-29  
1-Year Low: [--] on 2025-11-01  
  
  
### Galaxy Score: [-----]
![Galaxy Score Line Chart](https://lunarcrush.com/gi/w:600/t:$nvcr/c:line/m:galaxy_score/iv:1d.svg)  
[Galaxy Score 24-Hour Time-Series Raw Data](/topic/$nvcr/time-series/galaxy_score.tsv)  
Current Value: [-----]  
Daily Average: [--]  
[--] Week: [--] [---]  
[--] Month: [--] [---]  
[--] Months: [--] [---]  
[--] Year: [--] [---]  
1-Year High: [--] on 2025-06-10  
1-Year Low: [--] on 2025-10-30  
  
  
### Engagements: [------] (24h)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/t:$nvcr/c:line/m:interactions/iv:1d.svg)  
[Engagements 24-Hour Time-Series Raw Data](/topic/$nvcr/time-series/interactions.tsv)  
Current Value: [------]  
Daily Average: [-----]  
[--] Week: [-------] +977%  
[--] Month: [-------] +553%  
[--] Months: [-------] +11%  
[--] Year: [---------] -59%  
1-Year High: [-------] on 2026-02-12  
1-Year Low: [--] on 2025-12-21  

Engagements by network (24h):
Reddit: [--]
TikTok: [--]
News: [--]
X: [------]
YouTube: [---]

  
  
### Mentions: [---] (24h)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/t:$nvcr/c:line/m:posts_active/iv:1d.svg)  
[Mentions 24-Hour Time-Series Raw Data](/topic/$nvcr/time-series/posts_active.tsv)  
Current Value: [---]  
Daily Average: [--]  
[--] Week: [---] +1,142%  
[--] Month: [---] +340%  
[--] Months: [-----] -8.60%  
[--] Year: [-----] -9%  
1-Year High: [---] on 2026-02-14  
1-Year Low: [--] on 2025-12-21  

Mentions by network (24h):
Reddit: [--]
TikTok: [--]
News: [--]
X: [---]
YouTube: [--]

  
  
### Creators: [---] (24h)
![Creators Line Chart](https://lunarcrush.com/gi/w:600/t:$nvcr/c:line/m:contributors_active/iv:1d.svg)  
[Creators 24-Hour Time-Series Raw Data](/topic/$nvcr/time-series/contributors_active.tsv)  
[---] unique social accounts have posts mentioning NovoCure Limited Ordinary Shares (NVCR) in the last [--] hours which is down 19% from [---] in the previous [--] hours
Daily Average: [--]  
[--] Week: [---] +1,326%  
[--] Month: [---] +399%  
[--] Months: [---] -26%  
[--] Year: [-----] +30%  
1-Year High: [---] on 2026-02-14  
1-Year Low: [--] on 2025-12-21  

The most influential creators that mention NovoCure Limited Ordinary Shares in the last [--] hours

| Creator                                              | Rank | Followers | Posts | Engagements |
| -------                                              | ---- | --------- | ----- | ----------- |
| [@doepke_michel](/creator/twitter/doepke_michel)     | [--]    | [------]    | [--]     | [-----]       |
| [@ATP_Analytics](/creator/twitter/ATP_Analytics)     | [--]    | [-----]     | [--]    | [---]         |
| [@goldchart2](/creator/twitter/goldchart2)           | [--]    | [---]       | [--]    | [---]         |
| [@Stocktology](/creator/twitter/Stocktology)         | [--]    | [---]       | [--]     | [---]         |
| [@bn_trader](/creator/twitter/bn_trader)             | [--]    | [-----]     | [--]     | [---]         |
| [@henkletrade](/creator/twitter/henkletrade)         | [--]    | [--]        | [--]     | [---]         |
| [@TohJah7809](/creator/twitter/TohJah7809)           | [--]    | [-----]     | [--]     | [---]         |
| [@SpikeRadar](/creator/twitter/SpikeRadar)           | [--]    | [--]         | [--]     | [---]         |
| [@MarketRebellion](/creator/youtube/MarketRebellion) | [--]    | [------]    | [--]     | [---]         |
| [@BullionNation](/creator/twitter/BullionNation)     | [--]   | [-----]     | [--]     | [---]         |

[View More](/list/creators/$nvcr/100)
  
  
### Sentiment: 86%
![Sentiment Line Chart](https://lunarcrush.com/gi/w:600/t:$nvcr/c:line/m:sentiment/iv:1d.svg)  
[Sentiment 24-Hour Time-Series Raw Data](/topic/$nvcr/time-series/sentiment.tsv)  
Current Value: 86%  
Daily Average: 71%  
[--] Week: 77% -23%  
[--] Month: 80% no change  
[--] Months: 80% no change  
[--] Year: 80% +28%  
1-Year High: 100% on 2025-02-26  
1-Year Low: 8% on 2026-01-11  

Most Supportive Themes:
- FDA Approval for Pancreatic Cancer Treatment: (50%) NovoCure's Optune Pax device has received FDA approval for treating locally advanced pancreatic cancer, marking a significant advancement in treatment options.
- Positive Clinical Trial Data: (30%) The PANOVA-3 trial demonstrated improved overall survival and extended time to pain progression for patients using Optune Pax, highlighting the therapy's efficacy.
  
Most Critical Themes:
- Market Trends Impacting Price: (70%) Broader market trends are currently exerting downward pressure on NVCR's stock price, overshadowing positive company news and developments.
  
  
  
### Social Dominance: 0.03%
![Social Dominance Line Chart](https://lunarcrush.com/gi/w:600/t:$nvcr/c:line/m:social_dominance/iv:1d.svg)  
[Social Dominance 24-Hour Time-Series Raw Data](/topic/$nvcr/time-series/social_dominance.tsv)  
Current Value: 0.03%  
Daily Average: 0.00637%  
[--] Week: 0.114% +0.111%  
[--] Month: 0.059% +0.055%  
[--] Months: 0.059% +0.054%  
[--] Year: 0.059% +0.046%  
1-Year High: 0.059% on 2026-02-14  
1-Year Low: 0.0003% on 2025-12-21  
  
  
### Market Dominance: 0.0014%
![Market Dominance Line Chart](https://lunarcrush.com/gi/w:600/t:$nvcr/c:line/m:market_dominance/iv:1d.svg)  
[Market Dominance 24-Hour Time-Series Raw Data](/topic/$nvcr/time-series/market_dominance.tsv)  
Current Value: 0.0014%  
Daily Average: 0%  
1-Year High: 0.00879% on 2025-03-31  
1-Year Low: 0.00129% on 2026-02-09  
  
  
### Market Cap: $1,232,921,611
![Market Cap Line Chart](https://lunarcrush.com/gi/w:600/t:$nvcr/c:line/m:market_cap/iv:1d.svg)  
[Market Cap 24-Hour Time-Series Raw Data](/topic/$nvcr/time-series/market_cap.tsv)  
Current Value: $1,232,921,611  
Daily Average: $1,665,394,598  
[--] Week: $1,233,190,368 +8%  
[--] Month: $1,232,921,611 -20%  
[--] Months: $1,232,921,611 -8.80%  
[--] Year: $1,232,921,611 -49%  
1-Year High: $2,432,368,236 on 2025-02-15  
1-Year Low: $1,123,179,269 on 2026-02-09  

### Top NovoCure Limited Ordinary Shares Social Posts
Top posts by engagements in the last [--] hours

*Showing a maximum of [--] top social posts without a LunarCrush subscription.*

"🧬 Weekly & YTD Biotech Moves Week ending 02/13/26 $XBI: -2.11% ($122.86) πŸ”΄ $IBB: -1.39% ($172.55) πŸ”΄ Year-to-date $XBI: 0.76% 🟒 $IBB: 2.24% 🟒 See image below. πŸ‘‡ 🧬 Biotech Weekly News Largest single-day stock moves during the week ending 02/13/26 πŸ“ˆ $EVMN 71% EVO301 Topline data $NKTR 51% REZOLVE-AD Maintenance Data $HUMA 30% New Defense Funding for Blood Vessels $PHIO 24% Positive SMC wrap-up on PH-762 $NVCR 19% FDA Approves Optune https://t.co/RjwPL6kU1b 🧬 Biotech Weekly News Largest single-day stock moves during the week ending 02/13/26 πŸ“ˆ $EVMN 71% EVO301 Topline data $NKTR 51%"  
[X Link](https://x.com/BiopharmIQ/status/2022674375322018086) [@BiopharmIQ](/creator/x/BiopharmIQ) 2026-02-14T14:08Z 28.9K followers, [----] engagements


"🧬 Biotech Weekly News Largest single-day stock moves during the week ending 02/13/26 πŸ“ˆ $EVMN 71% EVO301 Topline data $NKTR 51% REZOLVE-AD Maintenance Data $HUMA 30% New Defense Funding for Blood Vessels $PHIO 24% Positive SMC wrap-up on PH-762 $NVCR 19% FDA Approves Optune Pax for Cancer πŸ“‰ $UPB -47% VALIANT Trial Results $MCRB -42% Program and Corporate Updates $CHRS -20% Pricing of Public Offering $1.75/sh $OKYO -19% Pricing of $20M Offering $1.85/sh $RGNX -14% Regulatory Update on RGX-121 BLA See image below. *** AD momentum continues. $NKTR maintenance data + early Ph2a from $EVMN in a"  
[X Link](https://x.com/BiopharmIQ/status/2022672827145650554) [@BiopharmIQ](/creator/x/BiopharmIQ) 2026-02-14T14:02Z 28.9K followers, [----] engagements


"$NVCR $ZLAB physics x biology πŸ‘‡πŸ‘€ https://x.com/ozdogan_md/status/2022342109030654174s=20 [--] Years Later: A New Hope for Pancreatic Cancer πŸŽ— #FDA has approved @Novocure 's #Optune Pax the first wearable electric field therapy for locally advanced pancreatic cancer. This non-invasive drug-free device uses TTFields technology to physically disrupt cancer cell https://t.co/jeRS6LYfYX https://x.com/ozdogan_md/status/2022342109030654174s=20 [--] Years Later: A New Hope for Pancreatic Cancer πŸŽ— #FDA has approved @Novocure 's #Optune Pax the first wearable electric field therapy for locally advanced"  
[X Link](https://x.com/TohJah7809/status/2022580686687998318) [@TohJah7809](/creator/x/TohJah7809) 2026-02-14T07:56Z [----] followers, [---] engagements


"$NVCR $ZLAB FDA Approves Novocures Optune Pax for the Treatment of Locally Advanced Pancreatic Cancer Finally after nearly [--] years something for locally-advanced pancreatic cancer Optune Pax is a wearable medical device that delivers Tumor Treating Fields (TTFields) alternating electric fields that disrupt cancer cell replication to cause cell death providing a new treatment approach for pancreatic tumors Novocure +9% only on the week on this news πŸ˜… πŸ₯ΌπŸ”¬πŸ§«πŸ§ͺπŸ¦ πŸ§¬πŸ’»πŸ§‘πŸ”¬πŸ€’πŸŒ‘πŸ’‰πŸ©ΈπŸ©ΉπŸ’ŠπŸ˜·πŸ©ΊπŸ₯βš• https://twitter.com/i/web/status/2022580681952358443 https://twitter.com/i/web/status/2022580681952358443"  
[X Link](https://x.com/TohJah7809/status/2022580681952358443) [@TohJah7809](/creator/x/TohJah7809) 2026-02-14T07:56Z [----] followers, [---] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing

NovoCure Limited Ordinary Shares (NVCR)

NovoCure's Optune Pax receives FDA approval for pancreatic cancer, but the stock faces downward pressure due to broader market trends.

About NovoCure Limited Ordinary Shares

NovoCure Limited Ordinary Shares (NVCR) is a healthcare company focused on TTFields therapy for cancer treatment.
NovoCure Limited Ordinary Shares uses the ticker $NVCR for trading. Listed in the Stocks category within the Healthcare sectors.

Insights

  • NovoCure Limited Ordinary Shares (NVCR) social dominance hit [------] which is 823% higher than it's daily average.
  • NovoCure Limited Ordinary Shares (NVCR) trading volume is up 182.93% from the previous week.
  • NovoCure Limited Ordinary Shares (NVCR) social dominance is up 6433.33% from the previous [--] months.
  • NovoCure Limited Ordinary Shares (NVCR) creators is up 1325.81% from the previous week.
  • NovoCure Limited Ordinary Shares (NVCR) engagements is up 976.86% from the previous week.
  • NovoCure Limited Ordinary Shares (NVCR) mentions is up 1142% from the previous week.
  • NovoCure Limited Ordinary Shares (NVCR) posts created is up 6816.67% from the previous week.
  • NovoCure Limited Ordinary Shares Creators hit a 52-Week high of [---] for the day
  • NovoCure Limited Ordinary Shares Creators hit an all time of [---] for the day
  • NovoCure Limited Ordinary Shares Mentions hit a 52-Week high of [---] for the day
  • NovoCure Limited Ordinary Shares Mentions hit an all time of [---] for the day
  • NovoCure Limited Ordinary Shares Engagements hit a 52-Week high of [-------] for the day

Price: $11

Price Line Chart
Price 24-Hour Time-Series Raw Data
Despite positive news like FDA approval for pancreatic cancer treatment, NVCR's price is experiencing downward pressure, likely due to broader market trends that are currently outweighing the positive social and corporate developments.

24-Hour: -12.11% 7-Day: 8.38% 30-Day: -19.43%

1-Year High: $22.50 on 2025-02-15
1-Year Low: $10 on 2026-02-09

AltRank: [---]

AltRank Line Chart
AltRank 24-Hour Time-Series Raw Data
NovoCure Limited Ordinary Shares (NVCR) is currently AltRank #861 based on combined combined social and market metrics Daily Average: [-----]
[--] Week: [---] [----]
[--] Month: [---] [------]
[--] Months: [---] [------]
[--] Year: [---] [----]
1-Year High: [-----] on 2026-01-29
1-Year Low: [--] on 2025-11-01

Galaxy Score: [-----]

Galaxy Score Line Chart
Galaxy Score 24-Hour Time-Series Raw Data
Current Value: [-----]
Daily Average: [--]
[--] Week: [--] [---]
[--] Month: [--] [---]
[--] Months: [--] [---]
[--] Year: [--] [---]
1-Year High: [--] on 2025-06-10
1-Year Low: [--] on 2025-10-30

Engagements: [------] (24h)

Engagements Line Chart
Engagements 24-Hour Time-Series Raw Data
Current Value: [------]
Daily Average: [-----]
[--] Week: [-------] +977%
[--] Month: [-------] +553%
[--] Months: [-------] +11%
[--] Year: [---------] -59%
1-Year High: [-------] on 2026-02-12
1-Year Low: [--] on 2025-12-21

Engagements by network (24h): Reddit: [--] TikTok: [--] News: [--] X: [------] YouTube: [---]

Mentions: [---] (24h)

Mentions Line Chart
Mentions 24-Hour Time-Series Raw Data
Current Value: [---]
Daily Average: [--]
[--] Week: [---] +1,142%
[--] Month: [---] +340%
[--] Months: [-----] -8.60%
[--] Year: [-----] -9%
1-Year High: [---] on 2026-02-14
1-Year Low: [--] on 2025-12-21

Mentions by network (24h): Reddit: [--] TikTok: [--] News: [--] X: [---] YouTube: [--]

Creators: [---] (24h)

Creators Line Chart
Creators 24-Hour Time-Series Raw Data
[---] unique social accounts have posts mentioning NovoCure Limited Ordinary Shares (NVCR) in the last [--] hours which is down 19% from [---] in the previous [--] hours Daily Average: [--]
[--] Week: [---] +1,326%
[--] Month: [---] +399%
[--] Months: [---] -26%
[--] Year: [-----] +30%
1-Year High: [---] on 2026-02-14
1-Year Low: [--] on 2025-12-21

The most influential creators that mention NovoCure Limited Ordinary Shares in the last [--] hours

Creator Rank Followers Posts Engagements
@doepke_michel [--] [------] [--] [-----]
@ATP_Analytics [--] [-----] [--] [---]
@goldchart2 [--] [---] [--] [---]
@Stocktology [--] [---] [--] [---]
@bn_trader [--] [-----] [--] [---]
@henkletrade [--] [--] [--] [---]
@TohJah7809 [--] [-----] [--] [---]
@SpikeRadar [--] [--] [--] [---]
@MarketRebellion [--] [------] [--] [---]
@BullionNation [--] [-----] [--] [---]

View More

Sentiment: 86%

Sentiment Line Chart
Sentiment 24-Hour Time-Series Raw Data
Current Value: 86%
Daily Average: 71%
[--] Week: 77% -23%
[--] Month: 80% no change
[--] Months: 80% no change
[--] Year: 80% +28%
1-Year High: 100% on 2025-02-26
1-Year Low: 8% on 2026-01-11

Most Supportive Themes:

  • FDA Approval for Pancreatic Cancer Treatment: (50%) NovoCure's Optune Pax device has received FDA approval for treating locally advanced pancreatic cancer, marking a significant advancement in treatment options.
  • Positive Clinical Trial Data: (30%) The PANOVA-3 trial demonstrated improved overall survival and extended time to pain progression for patients using Optune Pax, highlighting the therapy's efficacy.

Most Critical Themes:

  • Market Trends Impacting Price: (70%) Broader market trends are currently exerting downward pressure on NVCR's stock price, overshadowing positive company news and developments.

Social Dominance: 0.03%

Social Dominance Line Chart
Social Dominance 24-Hour Time-Series Raw Data
Current Value: 0.03%
Daily Average: 0.00637%
[--] Week: 0.114% +0.111%
[--] Month: 0.059% +0.055%
[--] Months: 0.059% +0.054%
[--] Year: 0.059% +0.046%
1-Year High: 0.059% on 2026-02-14
1-Year Low: 0.0003% on 2025-12-21

Market Dominance: 0.0014%

Market Dominance Line Chart
Market Dominance 24-Hour Time-Series Raw Data
Current Value: 0.0014%
Daily Average: 0%
1-Year High: 0.00879% on 2025-03-31
1-Year Low: 0.00129% on 2026-02-09

Market Cap: $1,232,921,611

Market Cap Line Chart
Market Cap 24-Hour Time-Series Raw Data
Current Value: $1,232,921,611
Daily Average: $1,665,394,598
[--] Week: $1,233,190,368 +8%
[--] Month: $1,232,921,611 -20%
[--] Months: $1,232,921,611 -8.80%
[--] Year: $1,232,921,611 -49%
1-Year High: $2,432,368,236 on 2025-02-15
1-Year Low: $1,123,179,269 on 2026-02-09

Top NovoCure Limited Ordinary Shares Social Posts

Top posts by engagements in the last [--] hours

Showing a maximum of [--] top social posts without a LunarCrush subscription.

"🧬 Weekly & YTD Biotech Moves Week ending 02/13/26 $XBI: -2.11% ($122.86) πŸ”΄ $IBB: -1.39% ($172.55) πŸ”΄ Year-to-date $XBI: 0.76% 🟒 $IBB: 2.24% 🟒 See image below. πŸ‘‡ 🧬 Biotech Weekly News Largest single-day stock moves during the week ending 02/13/26 πŸ“ˆ $EVMN 71% EVO301 Topline data $NKTR 51% REZOLVE-AD Maintenance Data $HUMA 30% New Defense Funding for Blood Vessels $PHIO 24% Positive SMC wrap-up on PH-762 $NVCR 19% FDA Approves Optune https://t.co/RjwPL6kU1b 🧬 Biotech Weekly News Largest single-day stock moves during the week ending 02/13/26 πŸ“ˆ $EVMN 71% EVO301 Topline data $NKTR 51%"
X Link @BiopharmIQ 2026-02-14T14:08Z 28.9K followers, [----] engagements

"🧬 Biotech Weekly News Largest single-day stock moves during the week ending 02/13/26 πŸ“ˆ $EVMN 71% EVO301 Topline data $NKTR 51% REZOLVE-AD Maintenance Data $HUMA 30% New Defense Funding for Blood Vessels $PHIO 24% Positive SMC wrap-up on PH-762 $NVCR 19% FDA Approves Optune Pax for Cancer πŸ“‰ $UPB -47% VALIANT Trial Results $MCRB -42% Program and Corporate Updates $CHRS -20% Pricing of Public Offering $1.75/sh $OKYO -19% Pricing of $20M Offering $1.85/sh $RGNX -14% Regulatory Update on RGX-121 BLA See image below. *** AD momentum continues. $NKTR maintenance data + early Ph2a from $EVMN in a"
X Link @BiopharmIQ 2026-02-14T14:02Z 28.9K followers, [----] engagements

"$NVCR $ZLAB physics x biology πŸ‘‡πŸ‘€ https://x.com/ozdogan_md/status/2022342109030654174s=20 [--] Years Later: A New Hope for Pancreatic Cancer πŸŽ— #FDA has approved @Novocure 's #Optune Pax the first wearable electric field therapy for locally advanced pancreatic cancer. This non-invasive drug-free device uses TTFields technology to physically disrupt cancer cell https://t.co/jeRS6LYfYX https://x.com/ozdogan_md/status/2022342109030654174s=20 [--] Years Later: A New Hope for Pancreatic Cancer πŸŽ— #FDA has approved @Novocure 's #Optune Pax the first wearable electric field therapy for locally advanced"
X Link @TohJah7809 2026-02-14T07:56Z [----] followers, [---] engagements

"$NVCR $ZLAB FDA Approves Novocures Optune Pax for the Treatment of Locally Advanced Pancreatic Cancer Finally after nearly [--] years something for locally-advanced pancreatic cancer Optune Pax is a wearable medical device that delivers Tumor Treating Fields (TTFields) alternating electric fields that disrupt cancer cell replication to cause cell death providing a new treatment approach for pancreatic tumors Novocure +9% only on the week on this news πŸ˜… πŸ₯ΌπŸ”¬πŸ§«πŸ§ͺπŸ¦ πŸ§¬πŸ’»πŸ§‘πŸ”¬πŸ€’πŸŒ‘πŸ’‰πŸ©ΈπŸ©ΉπŸ’ŠπŸ˜·πŸ©ΊπŸ₯βš• https://twitter.com/i/web/status/2022580681952358443 https://twitter.com/i/web/status/2022580681952358443"
X Link @TohJah7809 2026-02-14T07:56Z [----] followers, [---] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing

NovoCure Limited Ordinary Shares (NVCR)
/topic/$nvcr